Major Depression: Clinical Trials

21 trials for Major Depression, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

21 completed. 21 Phase 2, 4 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 221Completed 21
Phase 14Completed 4
Phase 31Completed 1

Follow Major Depression: new trials by email Literature Review of Major Depression trials Research Report on Major Depression

Trials (filtered) newest first · largest first

All 21 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Technology Enhanced Family Treatment
Family-Focused Treatment with MCC App - Mood Disorders, Bipolar Disorder
Phase 1 / Phase 2CompletedUniversity of California, Los Angeles652018-11-152024-05-28
A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder
SAGE-217, Placebo - Major Depression
Phase 2CompletedBiogen1022016-12-072023-11-28
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder
AV 101 (4-Chlorokynurenine), Placebo Comparator - Major Depression
Phase 2CompletedNational Institute of Mental Health (NIMH)222015-10-142022-04-11
Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression
Ayahuasca, placebo - Major Depression
Phase 1 / Phase 2CompletedUniversidade Federal do Rio Grande do Norte352014-02-012025-04-06
Deep Brain Stimulation of the Superolateral Branch of the Medial Forebrain Bundle (slMFB) for the Treatment of Refractory Major Depression
Deep Brain Stimulation with Activa PC Multi-program Neurostimulator - Major Depression
Phase 2CompletedUniversity Hospital, Bonn162013-07-012018-08-07
Trial of Transcranial Direct Current Stimulation (tDCS) for Depression
tDCS (Eldith DC-Stimulator (CE certified)) - Major Depression
Phase 2CompletedThe University of New South Wales32010-12-012015-09-17
Open Pilot Trial of TES for Depression
tDCS (Eldith DC-Stimulator (CE certified)) - Major Depression
Phase 2CompletedThe University of New South Wales72010-09-012015-12-02
Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions
Escitalopram, Placebo - TBI, Major Depression
Phase 2CompletedJohns Hopkins University162010-04-012016-10-24
Long-term Bilateral Theta Burst Stimulation for the Treatment of Major Depression
Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation, TBS) - Major Depression
Phase 2 / Phase 3CompletedUniversity Hospital Tuebingen322010-04-012013-07-16
Computerized Information-Processing Bias Retraining in Depressed Adolescents
Computerized Information-Processing Bias Retraining, Attention Control Training - Major Depression
Phase 2CompletedMassachusetts General Hospital482010-03-012012-05-03
A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive Disorder
SSR125543, escitalopram, placebo - Major Depression
Phase 2CompletedSanofi5802010-02-012011-04-14
Trial of Transcranial Direct Current Stimulation (tDCS) Using Alternative Electrode Montages
tDCS (Eldith DC-Stimulator (CE certified)) - Major Depression
Phase 2CompletedThe University of New South Wales292009-11-012016-05-24
N-methylglycine (Sarcosine) Treatment for Depression
citalopram, sarcosine - Major Depressive Disorder, Depression
Phase 2CompletedChina Medical University Hospital402009-04-012011-07-12
Evaluation of the H-Coil Transcranial Magnetic Stimulation(TMS) Device- Augmentation for Drug Resistant Depression
TMS - Major Depression
Phase 2CompletedBeerYaakov Mental Health Center402008-01-012009-10-06
Cimicoxib for the Treatment of Major Depression (SECIM)
Cimicoxib, Placebo - Major Depression
Phase 2CompletedAffectis Pharmaceuticals AG1692007-10-012013-11-13
Evaluation of the Deep TMS H-Coil in the Treatment of Major Depression- Augmentation of Antidepressant Medication
Transcranial Magnetic Stimulation (TMS) - Major Depression
Phase 1 / Phase 2CompletedHadassah Medical Organization572007-04-012015-03-20
Functional Neuroimaging in Depression
Oral administration of escitalopram during 8 weeks - Major Depression
Phase 2CompletedUniversity Hospital, Ghent402007-03-012010-08-31
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
Eicosapentaenoic acid (omega-3 fatty acid), Placebo - Schizophrenia, Schizoaffective Disorder
Phase 2CompletedUniversity of Pittsburgh572005-09-012017-04-10
Lexapro and Pramipexole and to Treat Major Depression
Pramipexole, Escitalopram - Major Depression
Phase 2CompletedNational Institute of Mental Health (NIMH)392004-06-012013-01-28
Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group
fluoxetine or desipramine - Major Depressive Disorder, Major Depression
Phase 2CompletedNational Institute of General Medical Sciences (NIGMS)7001999-11-012008-10-10

Showing 20 of 21. Sign in to see all of them.

Narrower conditions

Depressive Disorder, Major (21)  ·  Depression (11)  ·  Bipolar Disorder (2)  ·  Dysthymic Disorder (2)  ·  Mood Disorders (2)  ·  Anxiety Disorders (1)  ·  Behavior (1)  ·  Coronary Artery Disease (1)  ·  Depressive Disorder (1)  ·  Psychotic Disorders (1)  ·  Schizophrenia (1)

Broader conditions

Mental Disorders (21)  ·  Depressive Disorder (20)  ·  Mood Disorders (19)  ·  Behavioral Symptoms (11)  ·  Behavior (10)  ·  Bipolar and Related Disorders (2)  ·  Arterial Occlusive Diseases (1)  ·  Arteriosclerosis (1)  ·  Cardiovascular Diseases (1)  ·  Coronary Disease (1)  ·  Heart Diseases (1)  ·  Myocardial Ischemia (1)  ·  Schizophrenia Spectrum and Other Psychotic Disorders (1)  ·  Vascular Diseases (1)

Interventions

Escitalopram (3)  ·  Transcranial Direct Current Stimulation (3)  ·  Fluoxetine (2)  ·  Transcranial Magnetic Stimulation (2)  ·  4-chlorokynurenine (1)  ·  Citalopram (1)  ·  Deep Brain Stimulation (1)  ·  Desipramine (1)  ·  Eicosapentaenoic Acid (1)  ·  Fatty Acids, Omega-3 (1)  ·  Imipramine (1)  ·  Pramipexole (1)  ·  SSR125543 (1)  ·  Sarcosine (1)  ·  Soybean Oil (1)

Sponsors

The University of New South Wales (3)  ·  National Institute of Mental Health (NIMH) (2)  ·  Affectis Pharmaceuticals AG (1)  ·  BeerYaakov Mental Health Center (1)  ·  Biogen (1)  ·  China Medical University Hospital (1)  ·  Hadassah Medical Organization (1)  ·  Johns Hopkins University (1)  ·  Massachusetts General Hospital (1)  ·  National Institute of General Medical Sciences (NIGMS) (1)  ·  New York State Psychiatric Institute (1)  ·  Sanofi (1)  ·  Universidade Federal do Rio Grande do Norte (1)  ·  University Hospital Tuebingen (1)  ·  University Hospital, Bonn (1)

Countries

United States (9)  ·  Germany (4)  ·  Australia (3)  ·  Belgium (2)  ·  Israel (2)  ·  Austria (1)  ·  Brazil (1)  ·  Canada (1)  ·  Chile (1)  ·  Czechia (1)  ·  Estonia (1)  ·  Finland (1)  ·  France (1)  ·  Netherlands (1)  ·  Russia (1)

Top investigators

Carlos A Zarate, M.D. (2)  ·  Armen Arevian, MD (1)  ·  Chieh-Liang Huang, MD (1)  ·  Colleen Loo, MBBS (1)  ·  Colleen Loo, MBBS, FRANZCP, MD (1)  ·  David J Miklowitz, PhD (1)  ·  Draulio B de Araujo, Ph.D (1)  ·  Hsien-Yuan Lane, M.D., Ph.D (1)  ·  Jamie A Micco, PhD (1)  ·  Jeffrey K Yao, Ph.D., FACB (1)  ·  Jonathan W. Stewart, MD. (1)  ·  Julio Licinio, MD (1)  ·  Kurt Audenaert, MD, PhD (1)

Results publications

PMID 15365580, PMID 18061147, PMID 19414708, PMID 23562005, PMID 25220861, PMID 29903051, PMID 30253883, PMID 31231276, PMID 31798447, PMID 32236521, PMID 33128939, PMID 33360365, PMID 34510411, PMID 34817851, PMID 35378149, PMID 38094620, PMID 40109484, PMID 40494497, PMID 41257792, PMID 41743330, PMID 42171126, PMID 42498781, PMID 42521762

NIH funding

2009 (1), R34MH117200 (1)